Key facts
- Kimberly-Clark is preparing concessions to address EU antitrust concerns over its bid for Kenvue.
- The European Commission is expected to inform Kimberly-Clark of its concerns this week.
- The deal, announced last November, is valued at $40 billion.
- Kenvue is the maker of brands such as Tylenol, Listerine, Aveeno, and Neutrogena.
Kimberly-Clark is preparing concessions to address European Union antitrust concerns regarding its proposed $40 billion acquisition of Kenvue, according to people familiar with the matter. The EU competition enforcer is expected to inform Kimberly-Clark of its concerns this week, which could help the company gain approval for the deal after a preliminary review.